Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Regeneron Pharmaceuticals Insider Michael S. Brown Sells $1.69M of Stock
Michael S. Brown sold 1,929 shares of Regeneron Pharmaceuticals, Inc. at $875.00 a share, worth $1.69M in total on Oct 30, 2026. Shares held after the trade: 1,380 (-58.3%).
Financial Institutions Director Andrew W. Dorn Jr. Buys $63.2K of Stock
Andrew W. Dorn Jr., Director, bought 1,575 shares of Financial Institutions Inc at $40.11 a share, worth $63.2K in total on Nov 2, 2026. Shares held after the trade: 40,641 (+4.0%).
Braemar Hotels & Resorts Divestiture to Evergreen Acquisitions, LLC for $372M
Braemar Hotels & Resorts completed the sale of the 210-room Four Seasons Resort Scottsdale to Evergreen Acquisitions, LLC for $372 million in cash. The company expects to use the proceeds to fund remaining fees related to its transition to a self-managed REIT, which is on track for completion in mid-November 2026.
Acuity Inc. (De) President & CEO Neil Ashe Sells $4.23M of Stock
Neil Ashe, President & CEO, sold 13,217 shares of Acuity Inc. (De) at $313.98 to $325.07 a share (average $320.20) in 13 transactions, worth $4.23M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 64,858 (-1.5%).
Skyworks Solutions reported Q4 fiscal 2026 standalone revenue of $1.046 billion and non-GAAP diluted EPS of $1.28. The company highlighted the completion of its combination with Qorvo, which closed after the quarter end, creating a full-stack RF front-end platform targeting $500 million in annual cost synergies. For the full fiscal year 2026, Skyworks reported revenue of $3.96 billion.
“Combining with Qorvo gives us the scale and the technology breadth to lead the next era of wireless, as AI moves from the infrastructure to the devices, vehicles and machines around us.”
Phil Brace, chief executive officer and president of Skyworks
“Because our combination with Qorvo closed after the end of our fiscal fourth quarter, our reported September-quarter results are Skyworks standalone.”
Philip Carter, chief financial officer and senior vice president of Skyworks
Arvinas, Inc. reported total assets of $607.5 million as of September 30, 2026, a decrease from $717.9 million at the end of 2025, primarily driven by a reduction in marketable securities and the recognition of deferred revenue. The company maintains a cash runway expected to fund operations into the second half of 2028, focusing on clinical advancements for candidates like ARV-393 and ARV-027.
Artiva Biotherapeutics CEO Fred Aslan Sells $260K of Stock
Fred Aslan, CEO, sold 62,178 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $260K in total on Nov 2, 2026. Shares held after the trade: 1,457,428 (-4.1%).
Vertex Pharmaceuticals reported total revenues of $3.44 billion for the third quarter of 2026, a 12% increase compared to the same period in 2025. Net income for the quarter was $653.6 million, down from $1.08 billion in the prior year, primarily driven by significantly higher operating expenses and a $9.06 billion acquisition of Crinetics Pharmaceuticals.
Sotera Health reported a significant increase in net income for the nine months ended September 30, 2026, reaching $138.6 million compared to $43.1 million in the prior year period. This growth was driven by higher service revenues and the absence of the $64.9 million Illinois EO litigation settlement charge that impacted 2025 results.
Transcat Inc. reported total revenue of $97.1 million for the second quarter ended September 26, 2026, an 18% increase year-over-year, driven primarily by strong growth in Service revenue. Despite the revenue growth, net income for the six-month period decreased to $3.7 million from $4.5 million in the prior year, impacted by higher operating expenses and interest costs.
Knife River Corp delivered record aggregate margins but faced contracting headwinds; management launched 'Sharper Edge' to drive $125M in capital-led operational improvements amid public funding delays in Oregon and Idaho.
Parker-Hannifin Corporation held its 2026 Annual Meeting of Shareholders on October 28, 2026. Shareholders elected nine directors for terms expiring in 2027, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent accounting firm for fiscal year 2026.
Booking Holdings reported Q3 2026 financial results featuring 10% gross bookings growth and a 17% increase in adjusted EPS despite a 1% decline in GAAP revenue. The company recorded a $900 million revenue reduction related to an FTC matter and returned capital to shareholders through $2.1 billion in stock repurchases and a quarterly dividend declaration.
Term
Q3 2026
“We are pleased with our third-quarter operating performance, as resilient travel demand and disciplined execution by our teams drove double-digit gross bookings growth, margin expansion, and 17% adjusted earnings per share growth (GAAP earnings per share growth of 7%)”
Glenn Fogel, Chief Executive Officer of Booking Holdings
For the nine months ended September 30, 2026, UnitedHealth Group reported total revenues of $336.4 billion and net earnings attributable to common shareholders of $15.9 billion, an increase from $12.0 billion in the prior year period. The company maintained a strong balance sheet with $312.8 billion in total assets and returned $11.3 billion to shareholders through dividends and share repurchases during the first nine months of 2026.
Vulcan Materials SVP David P. Clement Sells $1.44M of Stock
David P. Clement, SVP, sold 5,000 shares of Vulcan Materials CO at $287.83 to $288.62 a share (average $287.86) in 2 transactions, worth $1.44M in total on Nov 2, 2026. Shares held after the trade: 1,716 (-10.4%).
Ardelyx reported Q3 2026 total product revenue of $125.5 million, a 19% increase year-over-year, driven primarily by $96.3 million in IBSRELA sales. The company reiterated its full-year 2026 revenue guidance for IBSRELA ($350M-$370M) and XPHOZAH ($110M-$120M) while maintaining a strong cash position of $285.3 million.
Term
Q3 2026
“Our third quarter results reflect the strength of the foundation we’ve built. IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, driven by strong performance from LIVMARLI and Bile Acid Medicines. The company increased its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the FDA approval and launch of ATEBRIOZ for FOP.
“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio. Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”
Transcat reported fiscal second quarter 2027 results featuring 18% total revenue growth to $97.1 million and 23% growth in its Service segment. The company achieved its 70th consecutive quarter of Service revenue growth and expanded Service gross margins by 220 basis points to 34%.
Term
Q2 2027
“Our fiscal second quarter results demonstrate strong execution across each pillar of our core strategy: driving strong Service organic revenue growth, expanding Service gross margins, executing strategic acquisitions, and growing Rentals consistently.”
Jaime Irick, President and CEO
“For the full fiscal year 2027, assuming the broader economic environment remains stable, we now expect Service organic revenue growth in the low double digits, up from our prior outlook of high single digits, along with Service gross margin expansion.”
Denali Therapeutics reported Q3 2026 financial results, highlighted by $17.8 million in net product revenue for AVLAYAH and a net income of $70.1 million. The company's cash position reached $1.0 billion, bolstered by a $194.0 million net gain from the sale of a Priority Review Voucher.
Term
Q3 2026
“Families and physicians are telling us that AVLAYAH is making a difference for children with Hunter syndrome, and the results this quarter reflect that. The positive responses to AVLAYAH across patients, physicians and payers, and our team’s strong commercial execution, show what is possible for our TransportVehicle portfolio.”
Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics
Avis Budget Group reported third quarter 2026 revenues of $3.4 billion and net income of $199 million. The company achieved record third-quarter Americas vehicle utilization of 74.1% and announced plans to redeem $350 million of its 5.750% Senior Notes due 2027.
Term
Q3 2026
“The third quarter demonstrated continued progress in how we manage our fleet, with third-quarter Americas utilization being the best we have had in twenty years despite a softer travel demand environment. We are building on the improvements we've made in fleet management and field operations with the objective of improving transaction economics, strengthening profitability, and delivering more consistent financial performance over time.”
Versant Media Group reported net income of $47 million for the third quarter of 2026, a decrease from $79 million in the prior year period, driven by lower revenues and higher interest expenses following its separation from Comcast. The company significantly increased its cash position to $1.05 billion and executed $300 million in share repurchases during the first nine months of the year.
Curaleaf Holdings reported record third-quarter 2026 revenue of $352.7 million, a 10.9% year-over-year increase driven by strong domestic and international growth. Despite the revenue record, the company reported a net loss from continuing operations of $37.4 million for the quarter, while maintaining an adjusted EBITDA margin of 22%.
Term
Q3 2026
“We are building the global leader in cannabis, and our third-quarter results provide further evidence that our strategy is delivering. Solid execution across the business is driving growth, strengthening our competitive position, and advancing our Built for Growth plan.”
Boris Jordan, Chairman and CEO
“These results reflect the disciplined execution of our entire team and reinforce the strength of our global platform. We are translating operational improvements into stronger financial performance, building momentum across the business, and positioning Curaleaf for sustained growth and greater cash generation.”
Axos Financial, Inc. filed a formal investor presentation deck (Exhibit 99.1) to be used in meetings with investors and analysts beginning November 4, 2026. The presentation outlines the company's investment thesis across its consumer banking, commercial banking, and securities divisions, highlighting its structural cost advantages and diversified growth strategy.
For the nine months ended September 30, 2026, Sixth Street Specialty Lending reported total investment income of $290.2 million and net investment income of $122.3 million, down from $159.5 million in the prior year period. Net asset value per share decreased to $16.19 from $16.98 at year-end 2025, primarily driven by net realized and unrealized losses totaling $73.4 million.
Generac Holdings CEO Aaron Jagdfeld Sells $1M of Stock
Aaron Jagdfeld, CEO, sold 5,000 shares of Generac Holdings Inc. at $200.61 a share, worth $1M in total on Nov 2, 2026. Shares held after the trade: 539,528 (-0.9%).
Paylocity Holding Insider Steven I. Sarowitz Sells $1.09M of Stock
Steven I. Sarowitz sold 6,374 shares of Paylocity Holding Corp at $170.22 to $172.36 a share (average $171.10) in 3 transactions, worth $1.09M in total on Oct 30, 2026. Shares held after the trade: 4,348,395 (-0.0%).
Regeneron Pharmaceuticals EVP Commercial Marion McCourt Sells $984K of Stock
Marion McCourt, EVP Commercial, sold 1,132 shares of Regeneron Pharmaceuticals, Inc. at $869.43 a share, worth $984K in total on Oct 30, 2026. Shares held after the trade: 10,871 (-9.4%).
Gladstone Commercial Corporation reported financial results for the third quarter ended September 30, 2026, including total operating revenue of $42.4 million. The company reported a net loss available to common stockholders of $5.2 million, or $0.11 per share, primarily impacted by a $6.5 million impairment charge. Core FFO for the quarter was $16.9 million, or $0.35 per diluted share.
Manitowoc reported strong third-quarter 2026 results with net sales of $613.8 million, up 10.9% year-over-year, and a 37.6% surge in orders to $676.4 million. Driven by robust crane demand in the Americas and Middle East, the company raised its full-year 2026 adjusted EBITDA and adjusted EPS guidance.
Term
Q3 2026
“Manitowoc’s third quarter results exceeded our expectations, highlighted by robust orders, double-digit sales growth, and a significant improvement in adjusted EBITDA. Backlog expanded over the last four consecutive quarters, reflecting continued strength in crane demand, particularly in the Americas, Middle East, and Asia Pacific, providing good visibility to the fourth quarter and into 2027.”
Aaron H. Ravenscroft, President and Chief Executive Officer
“For the remainder of the year, our priorities remain clear: execute against our backlog, improve working-capital efficiency, and continue to grow the aftermarket business through our CRANES+50 strategy. Given our strong momentum, we have raised our guidance for adjusted EBITDA and adjusted diluted earnings per share.”
Aaron H. Ravenscroft, President and Chief Executive Officer
Spyre Therapeutics reported third quarter 2026 financial results, highlighting a pro forma cash position of $1.5 billion following a $400 million public offering in October. The company achieved clinical proof-of-concept for its three IBD monotherapies and is advancing combination trials with data expected in Q3 2027.
Term
Q3 2026
“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.”
Cameron Turtle, DPhil, Chief Executive Officer of Spyre